Natera's Q3: Record Growth & Strategic Expansion
Update: 2025-11-08
Description
Nateras Q3 results exceeded expectations, with a 34% year-over-year sales increase to $592.2 million. The company raised its full-year revenue guidance to $2.22 billion, surpassing analyst predictions. Signateras strong adoption in oncology, along with improved pricing and operational investments, drove this success. Nateras womens health and organ health segments also grew, bolstered by the Fetal Focus test launch. Looking ahead, Natera expects continued oncology momentum, broader reimbursement, and strategic investments to fuel future growth.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
